Inhibikase Therapeutics Stock Price

-0.08 (-3.23%)
Upgrade to Real-Time
Afterhours (Closed)


52 Week Range


Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Pro
Monthly Subscription
for only
DDE w/Realtime (Monthly)
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Inhibikase Therapeutics Inc IKT NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.08 -3.23% 2.40 20:00:00
Open Price Low Price High Price Close Price Prev Close
2.48 2.35 2.52 2.44 2.48
Bid Price Ask Price Spread News
2.41 2.55 0.14 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
556 158,889 $ 2.41 $ 383,707 - 2.20 - 11.80
Last Trade Time Type Quantity Stock Price Currency
17:49:59 formt 292 $ 2.40 USD


Draw Mode:

Inhibikase Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 60.32M 25.13M 19.84M $ 698.47k $ - -0.35 -4.60
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 73.79k 21.00%

more financials information »

Inhibikase Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical IKT Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week2.592.592.202.39382,824-0.19-7.34%
1 Month3.,630-0.64-21.05%
3 Months5.316.412.202.96568,381-2.91-54.8%
6 Months6.899.162.203.54302,480-4.49-65.17%
1 Year10.6711.802.204.37313,378-8.27-77.51%
3 Years10.6711.802.204.37313,378-8.27-77.51%
5 Years10.6711.802.204.37313,378-8.27-77.51%

Inhibikase Therapeutics Description

Inhibikase Therapeutics Inc is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders. Its multi-therapeutic pipeline focuses on neurodegeneration and its lead program for IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, intends to treat Parkinson's disease inside and outside the brain. The company is performing its Phase I, randomized single ascending dose and multiple ascending dose, study to determine the safety, tolerability and pharmacokinetics of IkT-148009 in older and healthy subjects. It is also advancing a novel drug delivery platform to treat certain forms of cancer at the same time as it is developing novel drugs for the treatment of neurodegenerative disease.

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.